The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients

Abstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shuo Zhang, Beichen Liu, Mengli Zhou, Jintian Wang, Jinzhao Liu, Li Wang, Chao Yang, Yueping Liu, Shuyao Niu, Furong Du, Xiaohua Du, Ning Wang, Jiyu Tang, Chao Song, Yunjiang Liu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b8f9bf0eb917417294743488db621f33
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b8f9bf0eb917417294743488db621f33
record_format dspace
spelling oai:doaj.org-article:b8f9bf0eb917417294743488db621f332021-12-02T14:17:19ZThe beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients10.1038/s41598-021-87267-y2045-2322https://doaj.org/article/b8f9bf0eb917417294743488db621f332021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87267-yhttps://doaj.org/toc/2045-2322Abstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.Shuo ZhangBeichen LiuMengli ZhouJintian WangJinzhao LiuLi WangChao YangYueping LiuShuyao NiuFurong DuXiaohua DuNing WangJiyu TangChao SongYunjiang LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Shuo Zhang
Beichen Liu
Mengli Zhou
Jintian Wang
Jinzhao Liu
Li Wang
Chao Yang
Yueping Liu
Shuyao Niu
Furong Du
Xiaohua Du
Ning Wang
Jiyu Tang
Chao Song
Yunjiang Liu
The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
description Abstract RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.
format article
author Shuo Zhang
Beichen Liu
Mengli Zhou
Jintian Wang
Jinzhao Liu
Li Wang
Chao Yang
Yueping Liu
Shuyao Niu
Furong Du
Xiaohua Du
Ning Wang
Jiyu Tang
Chao Song
Yunjiang Liu
author_facet Shuo Zhang
Beichen Liu
Mengli Zhou
Jintian Wang
Jinzhao Liu
Li Wang
Chao Yang
Yueping Liu
Shuyao Niu
Furong Du
Xiaohua Du
Ning Wang
Jiyu Tang
Chao Song
Yunjiang Liu
author_sort Shuo Zhang
title The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
title_short The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
title_full The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
title_fullStr The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
title_full_unstemmed The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients
title_sort beneficial role of asian-based recurindex test in the prognostic prediction in chinese male breast cancer patients
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/b8f9bf0eb917417294743488db621f33
work_keys_str_mv AT shuozhang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT beichenliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT menglizhou thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jintianwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jinzhaoliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT liwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT chaoyang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT yuepingliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT shuyaoniu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT furongdu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT xiaohuadu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT ningwang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jiyutang thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT chaosong thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT yunjiangliu thebeneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT shuozhang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT beichenliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT menglizhou beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jintianwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jinzhaoliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT liwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT chaoyang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT yuepingliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT shuyaoniu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT furongdu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT xiaohuadu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT ningwang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT jiyutang beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT chaosong beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
AT yunjiangliu beneficialroleofasianbasedrecurindextestintheprognosticpredictioninchinesemalebreastcancerpatients
_version_ 1718391629037961216